GLP1R and familial pancreatic carcinoma: GLP1-RAs did not substantially raise the risk of cholelithiasis (MH-OR [95% CI] 1.30 [1.01–1.68], p = 0.041), while they did not significantly increase the incidence of pancreatitis or pancreatic cancer (MH-OR [95% CI] 0.93 [0.65–1.34], p = 0.71 and 0.94 [0.52–1.70], p = 0.84, respectively).